AstraZeneca PLC (LON:AZN) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of AstraZeneca PLC (LON:AZN - Get Free Report) have been given an average rating of "Moderate Buy" by the nine research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is £104.12 ($131.22).

Several equities research analysts have recently commented on the company. Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a report on Thursday, November 7th. JPMorgan Chase & Co. reaffirmed an "overweight" rating and issued a £140 ($176.43) price target on shares of AstraZeneca in a research note on Thursday, November 7th. Berenberg Bank restated a "buy" rating and set a £150 ($189.04) price target on shares of AstraZeneca in a report on Monday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a £110 ($138.63) target price on shares of AstraZeneca in a research note on Tuesday, September 3rd.

AstraZeneca Price Performance

Shares of LON:AZN traded down GBX 314 ($3.96) during trading hours on Friday, hitting GBX 9,978 ($125.75). 3,164,543 shares of the company's stock traded hands, compared to its average volume of 3,928,471. AstraZeneca has a 52 week low of GBX 9,461 ($119.23) and a 52 week high of £133.88 ($168.72). The company's fifty day simple moving average is £116.38 and its two-hundred day simple moving average is £121.23. The company has a market cap of £154.66 billion, a price-to-earnings ratio of 3,167.62, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89.

Insider Transactions at AstraZeneca

In related news, insider Michel Demare purchased 2,000 shares of the firm's stock in a transaction dated Friday, September 13th. The shares were acquired at an average cost of GBX 118 ($1.49) per share, with a total value of £2,360 ($2,974.17). Also, insider Pascal Soriot bought 20,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was purchased at an average cost of £102.03 ($128.58) per share, with a total value of £2,040,600 ($2,571,644.61). 0.04% of the stock is owned by insiders.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.